Compare ICMB & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | MDAI |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2M | 48.8M |
| IPO Year | 2013 | N/A |
| Metric | ICMB | MDAI |
|---|---|---|
| Price | $2.91 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 36.4K | ★ 213.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 17.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | $73.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $1.04 |
| 52 Week High | $3.38 | $3.21 |
| Indicator | ICMB | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 37.80 |
| Support Level | $2.75 | $1.32 |
| Resistance Level | $2.90 | $1.76 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.00 | 18.18 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.